Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension trial of ridaforolimus in advanced cancer
NCT00836927Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 2009
- Primary completion
- Apr 2017
- Modality
- Classical Binding Small Molecules
01
Overview
Phase 2, open-label trial of ridaforolimus in cancer (5 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced an Adverse Event and Number of Participants Who Discontinued Study Drug Due to an Adverse Event. Started Feb 2009; status: terminated.
02
Drugs
ridaforolimus
03
Conditions
cancer
Beyond the preview
Go deeper on NCT00836927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00836927.